• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LIANG Xin,XIAO Yan,ZHANG Mengqi,XIA Rui,ZHANG Yatong,GENG Xiaokun.Analysis of biospecimen management problems in drug clinical trials[J].Journal Of Pharmaceutical Research,2024,43(7):702-705,712[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3309times   Download 3775次 QR Code for this article
Scan with your phone!
药物临床试验中生物样本管理问题分析
梁欣1,肖妍2,张梦琦1,夏瑞1,张亚同3,耿晓坤1
Font:Larger+|Default|Smaller-
(1.首都医科大学附属北京潞河医院,北京 101149;2.中国食品药品检定研究院,北京 100050;3.北京医院,北京 100730)
摘要:
目的 对药物临床试验生物样本管理各环节存在的问题进行分析,并提出相应的处理措施,以保证临床试验的质量。方法 从我院药物临床试验管理系统中下载2019年5月至2023年5月已上报伦理委员的违背方案报告,对其中的生物样本管理相关违背进行回顾性分析,包括违背的类型、数量、责任主体、常见违背方案类型在不同临床试验分期中的分布、新版药物临床试验质量管理规范实施前后违背类型对比以及违背方案产生的影响。结果 纳入304份违背方案报告共涉及生物样本相关违背76例次,最常见的违背方案类型为样本储存超温(22例次,占比28.95%),采集超窗(14例次,占比18.42%),离心时间超窗(8例次,占比10.53%)。结论 通过完善生物样本质量管理体系、加强研究者GCP法规和方案培训,以提高研究者GCP意识及能力,产生高质量的生物样本、助力新药研发。
关键词:  药物临床试验  违背方案  生物样本管理
DOI:10.13506/j.cnki.jpr.2024.07.014
基金项目:国家重点研发计划(No.2020YFC2009001)
Publication Date:July 25, 2024
Analysis of biospecimen management problems in drug clinical trials
LIANG Xin1,XIAO Yan2,ZHANG Mengqi1,XIA Rui1,ZHANG Yatong3,GENG Xiaokun1
(1.Beijing Luhe Hospital Affiliated to Capital Medical University,Beijing 101149,China;2. National Institutes of Food and Drug Control, Beijing 100050,China;3.Beijing Hospital, Beijing 100730,China)
Abstract:
Objective To analyze the problems existing in the management of biological samples in drug clinical trials, and to propose corresponding measures to ensure the quality of clinical trials.Methods The violation protocol reports submitted to the ethics committee from May 2019 to May 2023 were downloaded from the drug clinical trial management system of our hospital, and the biospecimen management-related violations were retrospectively analyzed, including the type, quantity, responsible subject, distribution of common violation regimen types in different clinical trial stages, comparison of violation types before and after the implementation of the new version of drug clinical trial quality management standards, and the impact of violation of the protocol. Results A total of 76 cases of violations related to biological samples were included in the 304 protocol violation reports, and the most common types of protocol violations were sample storage over-temperature (22 cases, accounting for 28.95%), collection over-window (14 cases, accounting for 18.42%), and centrifugation time over-window (8 cases, accounting for 10.53%). Conclusion Improve the quality management system of biological samples, strengthen the training of investigators' GCP regulations and protocols, improve the awareness and ability of investigators' GCP, generate high-quality biological samples, and facilitate the research and development of new drugs.
Key words:  Drug clinical resarch  noncompliance/violation protocal  biological sample management
Today's Visits:488    Total Visits:2383203
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.